Bilateral descending hypothalamic projections to the spinal trigeminal nucleus caudalis in rats.
Several lines of evidence suggest that the hypothalamus is involved in trigeminal pain processing. However, the organization of descending hypothalamic projections to the spinal trigeminal nucleus caudalis (Sp5C) remains poorly understood. Microinjections of the retrograde tracer, fluorogold (FG), into the Sp5C, in rats, reveal that five hypothalamic nuclei project to the Sp5C: the paraventricular nucleus, the lateral hypothalamic area, the perifornical hypothalamic area, the A11 nucleus and the retrochiasmatic area. Descending hypothalamic projections to the Sp5C are bilateral, except those from the paraventricular nucleus which exhibit a clear ipsilateral predominance. Moreover, the density of retrogradely FG-labeled neurons in the hypothalamus varies according to the dorso-ventral localization of the Sp5C injection site. There are much more labeled neurons after injections into the ventrolateral part of the Sp5C (where ophthalmic afferents project) than after injections into its dorsomedial or intermediate parts (where mandibular and maxillary afferents, respectively, project). These results demonstrate that the organization of descending hypothalamic projections to the spinal dorsal horn and Sp5C are different. Whereas the former are ipsilateral, the latter are bilateral. Moreover, hypothalamic projections to the Sp5C display somatotopy, suggesting that these projections are preferentially involved in the processing of meningeal and cutaneous inputs from the ophthalmic branch of the trigeminal nerve in rats. Therefore, our results suggest that the control of trigeminal and spinal dorsal horn processing of nociceptive information by hypothalamic neurons is different and raise the question of the role of bilateral, rather than unilateral, hypothalamic control.
Clermont Université, Université d'Auvergne, NEURO-DOL: Trigeminal Pain and Migraine, BP 10448, Clermont-Ferrand; Inserm, U1107 Clermont-Ferrand, France.
Khaled
K
Abdallah
Alain
A
Artola
Lénaic
L
Monconduit
Radhouane
R
Dallel
Philippe
P
Luccarini
D000818:Animals; D005456:Fluorescent Dyes / Q000008:administration & dosage / Q000493:pharmacokinetics; D007031:Hypothalamus / Q000033:anatomy & histology / Q000166:cytology / Q000378:metabolism*; D007150:Immunohistochemistry; D008297:Male; D008845:Microinjections; D008953:Models, Anatomic; D009474:Neurons / Q000378:metabolism; D010286:Paraventricular Hypothalamic Nucleus / Q000033:anatomy & histology / Q000166:cytology / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013266:Stilbamidines / Q000008:administration & dosage / Q000493:pharmacokinetics; D014275:Trigeminal Caudal Nucleus / Q000033:anatomy & histology / Q000166:cytology / Q000378:metabolism*; D014279:Trigeminal Nucleus, Spinal / Q000033:anatomy & histology / Q000166:cytology / Q000378:metabolism*
C049774:2-hydroxy-4,4'-diamidinostilbene, methanesulfonate salt; D005456:Fluorescent Dyes; D013266:Stilbamidines